Ignite Creation Date:
2024-05-06 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05253066
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-02-23
First Post:
2022-01-13
Brief Title:
Chidamide Combined With Exemestane - Goserelin Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positiveHER2-negative Breast Cancer
Sponsor:
Shengjing Hospital
Organization:
Shengjing Hospital
Study Overview
Official Title:
An Open Multicenter Randomized Controlled Clinical Study of Chidamide Combined With Exemestane - Goserelin Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positiveHER2-negative Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open multicenter randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane - goserelin versus chemotherapy in the neoadjuvant treatment of stage II-III HR HER2- breast cancer patients with poor response to previous chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None